dr. (Ken) WK Redekop

All publications (161)

• Article (141)

  • Scholarly Publication (136)

    • A.M.M. Peultier, W.K. Redekop, D.W.J. Dippel, D. Bereczki, S. Si-Mohamed, P. Douek & J.L. Severens (2019). What stroke image do we want? European survey on acute stroke imaging and revascularisation treatment. Health Policy and Technology, 8 (33), 261-267. doi: 10.1016/j.hlpt.2019.08.005
    • A.M.M. Peultier, W.K. Redekop, M. Allen, J. Peters, O. Eker & J.L. Severens (2019). Exploring the Cost-Effectiveness of Mechanical Thrombectomy Beyond 6 Hours Following Advanced Imaging in the United Kingdom. Stroke. doi: 10.1161/STROKEAHA.119.026816
    • L.R. Buisman, A.J. Rijnsburger, A. van der Lugt, P.J. Nederkoorn, P.J. Koudstaal & W.K. Redekop (2019). Cost-effectiveness of novel imaging tests to select patients for carotid endarterectomy. Health Policy and Technology, 8 (2), 111-117. doi: 10.1016/j.hlpt.2019.05.001 [go to publisher's site]
    • A.M.M. Peultier, W.K. Redekop, M. Allen, J. Peters, O. Eker & J.L. Severens (2019). Exploring the Cost-Effectiveness of Mechanical Thrombectomy Beyond 6 Hours Following Advanced Imaging in the United Kingdom. Stroke, 50 (11), 3220-3227. doi: 10.1161/strokeaha.119.026816
    • S. Nestler-Parr, D. Korchagina, M. Toumi, C.L. Pashos, C. Blanchette, E. Molsen, T. Morel, S. Simoens, Z. Kalo, R. Gatermann & W.K. Redekop (2018). Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group. Value in Health, 21 (5), 493-500. doi: 10.1016/j.jval.2018.03.004 [go to publisher's site]
    • W.K. Redekop, L.J. Bakker & J.E.C.M. Aarts (2018). Healthcare problems cannot be solved using health technologies alone: The example of precision medicine. Health Policy and Technology, 7 (1), 3-4. doi: 10.1016/j.hlpt.2018.01.006 [go to publisher's site]
    • E.J. Lenk, W.K. Redekop, M. Luyendijk, C. Fitzpatrick, L. Niessen, W.A. Stolk, F. Tediosi, A.J. Rijnsburger, R. Bakker, J.A.C. Hontelez, J.H. Richardus, J. Jacobson, E.A. Le Rutte, S.J. de Vlas & J.L. Severens (2018). Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease. PLoS Neglected Tropical Diseases (online), 12 (3):e0006250. doi: 10.1371/journal.pntd.0006250
    • T.A. Kanters, W.K. Redekop & L. Hakkaart - van Roijen (2018). International differences in patient access to ultra-orphan drugs. Health Policy and Technology, 7, 57-64. doi: 10.1016/j.hlpt.2017.12.001
    • S. de Groot, W.K. Redekop, M.M. Versteegh, S. Sleijfer, E. Oosterwijk, L.A.L.M. Kiemeney & C.A. de Uyl-de Groot (2018). Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma. Quality of Life Research. doi: 10.1371/journal.pone.0177364
    • W.K. Redekop (2018). Fake news, big data, and the opportunities and threats of targeted actions. Health Policy and Technology, 7 (2), 113-114. doi: 10.1016/j.hlpt.2018.05.001 [go to publisher's site]
    • A. Ansaripour, K. Zendehdel, N. Tadayon, F. Sadeghi, C.A. Uyl - de Groot & W.K. Redekop (2018). Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran. PLoS One (online), 13 (10). doi: 10.1371/journal.pone.0205079
    • A. Ansaripour, C.A. Uyl - de Groot & W.K. Redekop (2018). Response to 'Comment on ''Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy"'. Pharmacoeconomics (Print), 36 (3), 381-382. doi: 10.1007/s40273-018-0620-y
    • A.M.M. Peultier, W.K. Redekop, E. Coche & J.L. Severens (2018). What are the images used to diagnose and assess suspected strokes?: A systematic literature review of care in four European countries. Expert review of pharmacoeconomics & outcomes research, Volume 18 (2). doi: 10.1080/14737167.2018.1429270
    • W.K. Redekop (2017). Mapping the dimensions of Health Policy and Technology. Health Policy and Technology, 6 (2), 121-123. doi: 10.1016/j.hlpt.2017.05.001 [go to publisher's site]
    • S. de Groot, H.M. Blommestein, W.K. Redekop, S. Sleijfer, L. Kiemeney, E. Oosterwijk & C.A. de Uyl-de Groot (2017). Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments. PLoS One (print), 12 (5):e0177364. doi: 10.1371/journal.pone.0177364
    • F. Paolucci, W.K. Redekop, A. Fouda & G. Fiorentini (2017). Decision Making and Priority Setting: The Evolving Path Towards Universal Health Coverage. Applied Health Economics and Health Policy, 15 (6), 697-706. doi: 10.1007/s40258-017-0349-3
    • W.K. Redekop, E.J. Lenk, M. Luyendijk, C. Fitzpatrick, L. Niessen, W.A. Stolk, F. Tediosi, A.J. Rijnsburger, R. Bakker, J.A.C. Hontelez, J.H. Richardus, J. Jacobson, S.J. de Vlas & J.L. Severens (2017). The Socioeconomic Benefit to Individuals of Achieving the 2020 Targets for Five Preventive Chemotherapy Neglected Tropical Diseases. PLoS Neglected Tropical Diseases (online), 11 (1):e0005289. doi: 10.1371/journal.pntd.0005289
    • A. Ansaripour, H.B. Thio, R. Maessen & W.K. Redekop (2017). The cost–effectiveness of blue-light therapy in the treatment of mild-to-moderate psoriasis. Journal of comparative effectiveness research. doi: 10.2217/cer-2017-0007
    • T.A. Kanters, A.T. van der Ploeg, M.E. Kruijshaar, D. Rizopoulos, W.K. Redekop, M.P.M.H. Rutten - van Molken & L. Hakkaart - van Roijen (2017). Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease. Orphanet Journal of Rare Diseases, 12:179. doi: 1186/s13023-017-0731-0 [go to publisher's site]
    • S. de Groot, S. Sleijfer, W.K. Redekop, E. Oosterwijk, J. Haanen, L.A.L.M. Kiemeney & C.A. de Uyl-de Groot (2016). Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry. Bmc Cancer, 16, 364. doi: 10.1186/s12885-016-2395-x
    • S. de Groot, W.K. Redekop, S. Sleijfer, E. Oosterwijk, A. Bex, L.A.L.M. Kiemeney & C.A. de Uyl-de Groot (2016). Survival in patients with primary metastatic renal cell carcinoma treated with sunitinib with or without previous cytoreductive nephrectomy: Results from a population-based registry. Urology, 95, 121-127. doi: 10.1016/j.urology.2016.04.042
    • L.T. Burgers, W.K. Redekop, M.J. Al, S.K. Lhachimi, N. Armstrong, S. Walker, C. Rothery, M. Westwood & J.L. Severens (2016). Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients. European Journal of Health Economics (HEPAC), 1-12. doi: 10.1007/s10198-016-0824-z
    • H.J. Fugel, M. Nuijten, M. Postma & W.K. Redekop (2016). Economic evaluation in stratified medicine: methodological issues and challenges. Frontiers in pharmacology, 7:113. doi: 10.3389/fphar.2016.00113
    • C.A. van Bochove, L.T. Burgers, A. Vahl, E. Birnie, M.G. van Schothorst & W.K. Redekop (2016). Cost-effectiveness of open versus endovascular repair of abdominal aortic aneurysm. Journal of Vascular Surgery, 63 (3), 827-838. doi: 10.1016/j.jvs.2015.10.055
    • T.I. Verhoef, W.K. Redekop, S. Langenskiold, F. Kamali, M. Wadelius, G. Burnside, A.H. Maitland-van der Zee, D.A. Hughes & M. Pirmohamed (2016). Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden. Pharmacogenomics Journal, 16 (5), 478-484. doi: 10.1038/tpj.2016.41
    • A. Ansaripour, C.A. de Uyl-de Groot, M. Foroozanfar, S. Rahimimoghadam & W.K. Redekop (2016). Which is more important for doctors in a middle-income country, a national guideline or the medical literature? An adherence survey of trastuzumab use for breast cancer in Iran. Journal of Cancer Policy, 9, 8-13. doi: 10.1016/j.jcpo.2016.05.005
    • L.R. Buisman, M.P.M.H. Rutten - van Molken, D. Postmus, J.J. Luime, C.A. de Uyl-de Groot & W.K. Redekop (2016). The early bird catches the worm: early cost-effectiveness analysis of new medical tests. International Journal of Technology Assessment in Health Care, 32 (1-2), 46-53. doi: 10.1017/S0266462316000064
    • E.J. Lenk, W.K. Redekop, M. Luyendijk, A.J. Rijnsburger & J.L. Severens (2016). Productivity Loss Related to Neglected Tropical Diseases Eligible for Preventive Chemotherapy: A Systematic Literature Review. PLoS Neglected Tropical Diseases (print), 10 (2), 1-19. doi: 10.1371/journal.pntd.0004397
    • N.T. Rosendaal, M.E. Hendriks, M.D. Verhagen, O.A. Bolarinwa, E.O. Sanya, P.M. Kolo, P. Adenusi, K. Agbede, D. van Eck, S.S. Tan, T.M. Akande, W.K. Redekop, C. Schultsz & G.B. Gomez (2016). Costs and Cost-Effectiveness of Hypertension Screening and Treatment in Adults with Hypertension in Rural Nigeria in the Context of a Health Insurance Program. PLoS One (print), 11 (6), e0157925. doi: 10.1371/journal.pone.0157925
    • R.M. Oemrawsingh, K.M. Akkerhuis, L.C. van Vark, W.K. Redekop, G. Rudez, W.J. Remme, M.E. Bertrand, K.M. Fox, R. Ferrari, A. Danser, M.P.M. de Maat, M.L. Simoons, J.J. Brugts & E. Boersma (2016). Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model. Journal of the American Heart Association, 5 (3), e002688. doi: 10.1161/JAHA.115.002688
    • B. Wijnen, G. van Mastrigt, W.K. Redekop, H. Majoie, R. de Kinderen & S. Evers (2016). How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3/3). Expert review of pharmacoeconomics & outcomes research, 16 (6), 723-732. doi: 10.1080/14737167.2016.1246961
    • L.T. Burgers, F. van de Wetering, J.L. Severens & W.K. Redekop (2016). Using meta-regression analyses in addition to conventional systematic review methods to examine the variation in cost-effectiveness results - a case study. Bmc Health Services Research, 16 (23). doi: 10.1186/s12913-015-1230-4
    • S.J. de Vlas, W.A. Stolk, E.A. Le Rütte, J.A.C. Hontelez, R. Bakker, D.J. Blok, R. Cai, T.A.J. Houweling, M.C. Kulik, E.J. Lenk, M. Luyendijk, S.M. Matthijsse, W.K. Redekop, I.M. Wagenaar, J. Jacobson, N.J.D. Nagelkerke & J.H. Richardus (2016). Concerted Efforts to Control or Eliminate Neglected Tropical Diseases: How Much Health Will Be Gained? PLoS Neglected Tropical Diseases (print), 10 (2). doi: 10.1371/journal.pntd.0004386
    • L.T. Burgers, A. Vahl, J.L. Severens, A. Wiersema, P.W.M. Cuypers, H.J.M. Verhagen & W.K. Redekop (2016). Cost-effectiveness of Elective Endovascular Aneurysm Repair Versus Open Surgical Repair of Abdominal Aortic Aneurysms. European Journal of Vascular and Endovascular Surgery, 52 (1), 29-40. doi: 10.1016/j.ejvs.2016.03.001
    • L.R. Buisman, A.J. Rijnsburger, H. den Hertog, A. van der Lugt & W.K. Redekop (2016). Clinical Practice Variation Needs to be Considered in Cost-Effectiveness Analyses: A Case Study of Patients with a Recent Transient Ischemic Attack or Minor Ischemic Stroke. Applied Health Economics and Health Policy, 14 (1), 67-75. doi: 10.1007/s40258-015-0167-4
    • A. van Dongen - Leunis, W.K. Redekop & C.A. Uyl - de Groot (2016). Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30. Value in Health, 19 (6), 834-843. doi: 10.1016/j.jval.2016.05.008
    • L.R. Buisman, S.S. Tan, P.J. Nederkoorn, P.J. Koudstaal & W.K. Redekop (2015). Hospital costs of ischemic stroke and TIA in the Netherlands. Neurology, 84 (22), 2208-2215. doi: 10.1212/WNL.0000000000001635
    • T.A. Kanters, W.K. Redekop, M.P.M.H. Rutten - van Molken, M.E. Kruijshaar, D. Güngör, A.T. van der Ploeg & L. Hakkaart-van Roijen (2015). A conceptual disease model for adult Pompe disease. Orphanet Journal of Rare Diseases, 10:112. doi: 10.1186/s13023-015-0334-6
    • T.A. Kanters, L. Hakkaart-van Roijen, M.P.M.H. Rutten - van Molken & W.K. Redekop (2015). Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug? Expert review of pharmacoeconomics & outcomes research, 15 (4), 557-559. doi: 10.1586/14737167.2015.1045882
    • M.E. Hendriks, O.A. Bolarinwa, H. Nelissen, A.C. Boers, G.B. Gomez, S.S. Tan, W.K. Redekop, P. Adenusi, J.M.A. Lange, K. Agbede, T.M. Akande & C. Schultsz (2015). Costs of cardiovascular disease prevention care and scenarios for cost saving: a micro-costing study from rural Nigeria. Journal of Hypertension, 33 (2), 376-684. doi: 10.1097/HJH.0000000000000402
    • S. de Groot, A.J. Rijnsburger, M.M. Versteegh, J.M. Heymans, S. Kleijnen, W.K. Redekop & I. Verstijnen (2015). Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers. BMJ Open, 5::e007241. doi: 10.1136/bmjopen-2014-007241
    • L.T. Burgers, E. McClellan, I. Hoefer, G. Pasterkamp, J.W. Jukema, S. Horsman, N. Pijls, J. Waltenberger, M. Hillaert, A. Stubbs, J.L. Severens & W.K. Redekop (2015). Treatment variation in stent choice in patients with stable or unstable coronary artery disease. Netherlands Heart Journal, 24, 110-119. doi: 10.1007/s12471-015-0783-5
    • L.M.A. Goossens, W.K. Redekop & C.W.M. van Gils (2015). Noncollapsibility and Censoring: What's the Bias in Estimating Effects on Survival? Epidemiology, 26 (1), e1-e2. doi: 10.1097/EDE.0000000000000197
    • K.M. Goor, J.G. Gaultney, P. van Houten, A.S. Wagg, S.A. Huygens, M.M. Nielen, C.P. Albers-Heitner, W.K. Redekop, M.P.M.H. Rutten - van Molken & M.J. Al (2015). Cost-Effectiveness of Including a Nurse Specialist in the Treatment of Urinary Incontinence in Primary Care in the Netherlands. PLoS One (print), 10 (10). doi: 10.1371/journal.pone.0138225
    • T.A. Kanters, W.K. Redekop, M.E. Kruijshaar, A.T. van der Ploeg, M.P.M.H. Rutten - van Molken & L. Hakkaart-van Roijen (2015). Comparison of EQ-5D and SF-6D utilities in Pompe disease. Quality of Life Research, 24, 837-844. doi: 10.1007/s11136-014-0833-2
    • J.G. Gaultney, M.G. Franken, C.A. de Uyl-de Groot, W.K. Redekop, P.C. Huijgens, B. van der Holt, H.M. Lokhorst & P. Sonneveld (2015). Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursement. Health Policy, 119 (2), 186-194. doi: 10.1016/j.healthpol.2014.11.010
    • C.W.M. van Gils, S. de Groot, S.S. Tan, W.K. Redekop, M. Koopman, C. Punt & C.A. de Uyl-de Groot (2015). Real-world resource use and costs of adjuvant treatment for stage III colon cancer. European Journal of Cancer Care, 24 (3), 321-332. doi: 10.1111/ecc.12154
    • T.I. Verhoef, W.K. Redekop, F. Hasrat, A. de Boer & A.H. Maitland-van der Zee (2014). Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings. American Journal of Cardiovascular Drugs, 14 (6), 451-462. doi: 10.1007/s40256-014-0092-1
    • M.G. Franken, J.G. Gaultney, H.M. Blommestein, P.C. Huijgens, P. Sonneveld, W.K. Redekop & C.A. de Uyl-de Groot (2014). Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib? Value in Health, 17, 245-253. doi: 10.1016/j.jval.2013.12.009
    • M.E. Hendriks, P. Kundu, A.C. Boers, O.A. Bolarinwa, M.J. te Pas, T.M. Akande, K. Agbede, G.B. Gomez, W.K. Redekop, C. Schultsz & S.S. Tan (2014). Step-by-step Guideline for disease-specific costing studies in low and middle income countries: a mixed methodology. Global Health Action, 28 (7), 23573. doi: 10.3402/gha.v7.23573
    • J.C. Rejon-Parrilla, N. Nuijten, W.K. Redekop & J.G. Gaultney (2014). Economic evaluation of the use of a pharmacogenetic diagnostic test in schizophrenia. Health Policy and Technology, 3 (4), 314-324. doi: 10.1016/j.hlpt.2014.08.004
    • L.T. Burgers, S.T. Nauta, J.W. Deckers, J.L. Severens & W.K. Redekop (2014). Is it cost-effective to use a test to decide which individuals with an intermediate cardiovascular disease risk would benefit from statin treatment? International Journal of Cardiology, 176 (3), 980-987. doi: 10.1016/j.ijcard.2014.08.134
    • T.I. Verhoef, W.K. Redekop, M. Bouvy, B. Dorenbos, Z. Karwar, R.M. van Schie, A. de Boer & A.H. Maitland-van der Zee (2014). Beliefs about medicines in Dutch acenocoumarol and phenprocoumon users. British Journal of Clinical Pharmacology, 78 (2), 422-429. doi: 10.1111/bcp.12346
    • W.K. Redekop (2014). Tools and techniques - statistics: comments on a cost-effectiveness study of TAVI for patients with inoperable aortic stenosis. EuroIntervention, 9 (10), 1241-1243. doi: 10.4244/EIJV9I10A208
    • H. Versteeg, S.S. Pedersen, M. Mastenbroek, W.K. Redekop, J.O. Schwab, P. Mabo & M. Meine (2014). Patient perspective on remote monitoring of cardiovascular implantable electronic devices: rationale and design of the REMOTE-CIED study. Netherlands Heart Journal, 22 (10), 423-428. doi: 10.1007/s12471-014-0587-z
    • L.T. Burgers, W.K. Redekop & J.L. Severens (2014). Challenges in Modelling the Cost Effectiveness of Various Interventions for Cardiovascular Disease. Pharmacoeconomics (Print), 32 (7), 627-637. doi: 10.1007/s40273-014-0155-9
    • S.S. Tan, A. Geissler, L. Serden, M. Heurgren, B.M. van Ineveld, W.K. Redekop & L. Hakkaart-van Roijen (2014). DRG systems in Europe: variations in cost accounting systems among 12 countries. European Journal of Public Health, 24 (6), 1023-1028. doi: 10.1093 [go to publisher's site]
    • T.A. Kanters, I. Hoogenboom-Plug, M.P.M.H. Rutten - van Molken, W.K. Redekop, A.T. van der Ploeg & L. Hakkaart-van Roijen (2014). Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease. Orphanet Journal of Rare Diseases, 9, 75. doi: 10.1186/1750-1172-9-75
    • A. Ansaripour, C.A. de Uyl-de Groot, A. Steenhoek & W.K. Redekop (2014). The Drug Reimbursement Decision-Making System in Iran. Value in Health Regional Issues, 3, 174-181. doi: 10.1016/j.vhri.2014.04.010
    • T.I. Verhoef, W.K. Redekop, A.K. Daly, R.M. van Schie, A. de Boer & A.H. Maitland-van der Zee (2014). Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. British Journal of Clinical Pharmacology, 77 (4), 626-641. doi: 10.1111/bcp.12220
    • A. Leunis, W.K. Redekop, C.A. de Uyl-de Groot & B. Lowenberg (2014). Impaired health-related quality of life in acute myeloid leukemia survivors: a single-center study. European Journal of Haematology, 93 (3), 196-206. doi: 10.1111/ejh.12324
    • L. Annemans, W.K. Redekop & K. Payne (2013). Current Methodological Issues in the Economic Assessment of Personalized Medicine. Value in Health, 16, 20-26. doi: 10.1016/j.jval.2013.06.008
    • M.G. Franken, C.W.M. van Gils, J.G. Gaultney, G. Delwel, W. Goettsch, P.C. Huijgens, A. Steenhoek, C.J.A. Punt, M. Koopman, W.K. Redekop & C.A. de Uyl-de Groot (2013). Practical feasibility of outcomes research in oncology: Lessons learned in assessing drug use and cost-effectiveness in The Netherlands. European Journal of Cancer, 49, 8-16. doi: 10.1016/j.ejca.2012.06.010
    • I. Hoefer, J. Sels, J.W. Jukema, S. Bergheanu, E. Biessen, E. McClellan, M. Daemen, P. Doevendans, P. de Groot, M. Hillaert, S. Horsman, M. Ilhan, J. Kuiper, N. Pijls, W.K. Redekop, P. van der Spek, A. Stubbs, E. van de Veer, J. Waltenberger, A.J. van Zonneveld & G. Pasterkamp (2013). Circulating cells as predictors of secondary manifestations of cardiovascular disease: design of the CIRCULATING CELLS study. Clinical Research in Cardiology, 102, 847-856. doi: 10.1007/s00392-013-0607-9
    • M. Sunamura, N. ter Hoeve, H.J.G. van den Berg-Emons, M. Haverkamp, W.K. Redekop, M.L. Geleijnse, H.J. Stam, E. Boersma & R.T. van Domburg (2013). OPTImal CArdiac REhabilitation (OPTICARE) following Acute Coronary Syndromes: Rationale and design of a randomised, controlled trial to investigate the benefits of expanded educational and behavioural intervention programs. Netherlands Heart Journal, 21 (7-8), 324-330. doi: 10.1007/s12471-013-0422-y
    • M. Westwood, M. Joore, J.C. Grutters, W.K. Redekop, N. Armstrong, K. Lee, V. Gloy, H. Raatz, K. Misso, J.L. Severens & J. Kleijnen (2013). Contrast-enhanced ultrasound using SonoVue (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 17 (16), 1-243. doi: 10.3310/hta17160
    • C.W.M. van Gils, S. de Groot, W.K. Redekop, M. Koopman, C.J.A. Punt & C.A. de Uyl-de Groot (2013). Real-World Cost-Effectiveness of Oxaliplatin in Stage III Colon Cancer: A Synthesis of Clinical Trial and Daily Practice Evidence. Pharmacoeconomics (Print), 31 (8), 703-718. doi: 10.1007/s40273-013-0061-6
    • W.K. Redekop & D. Mladsi (2013). The faces of personalized medicine: a framework for understanding its meaning and scope. Value in Health, 16 (6 Suppl), S4-S9. doi: 10.1016/j.jval.2013.06.005
    • T.I. Verhoef, G. Ragia, A. de Boer, R. Barallon, G. Kolovou, V. Kolovou, S. Konstantinides, S. Le Cessie, E. Maltezos, F.J. van der Meer, W.K. Redekop, M. Remkes, F.R. Rosendaal, R.M. van Schie, A. Tavridou, D. Tziakis, M. Wadelius, V.G. Manopoulos & A.H. Maitland-van der Zee (2013). A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. New England Journal of Medicine, 369 (24), 2304-2312. doi: 10.1056/NEJMoa1311388
    • T.A. Kanters, C. de Sonneville-Koedoot, W.K. Redekop & L. Hakkaart-van Roijen (2013). Systematic review of available evidence on 11 high-priced inpatient orphan drugs. Orphanet Journal of Rare Diseases, 8. doi: 10.1186/1750-1172-8-124
    • T.A. Kanters, I. Plug, M.P.M.H. van Molken, W.K. Redekop, A.T. van der Ploeg & L. Hakkaart-van Roijen (2013). Cost-effectiveness of enzyme replacement therapy (ERT) with alglucosidase alfa in classic-infantile patients with Pompe disease. Value in Health, 16 (7), A384-A384. doi: 10.1016/j.jval.2013.08.353
    • J.G. Gaultney, M.G. Franken, S.S. Tan, W.K. Redekop, P.C. Huijgens, P. Sonneveld & C.A. de Uyl-de Groot (2013). Real-world healthcare costs of relapsed/refractory multiple myeloma during the era of novel cancer agents. Journal of Clinical Pharmacy and Therapeutics, 38, 41-47. doi: 10.1111/jcpt.12020
    • L.C. Battes, I. Kardys, R.J. Barendse, E.W. Steyerberg, M. Amiri, M.J.C. Eijkemans, J.W. Deckers, D. Postmus, J.J.M. Takkenberg, W.K. Redekop & E. Boersma (2013). Microsimulation for Clinical Decision-Making in Individual Patients With Established Coronary Artery Disease - A Concept. Circulation Journal, 77 (3), 717-724. doi: 10.1253/circj.CJ-11-1300
    • A. Leunis, W.K. Redekop, C.A.G.M. van Montfort, B. Lowenberg & C.A. de Uyl-de Groot (2013). The Development and Validation of a Decision-Analytic Model Representing the Full Disease Course of Acute Myeloid Leukemia. Pharmacoeconomics (Print). doi: 10.1007/s40273-013-0058-1
    • R.R. Soekhlal, L.T. Burgers, W.K. Redekop & S.S. Tan (2013). Treatment costs for acute myocardial infarction in the Netherlands. Netherlands Heart Journal. doi: 10.1007/s12471-013-0386-y
    • C.O. Agyemang, A.E. Kunst, R. Bhopal, P. Zaninotto, J. Nazroo, N. Unwin, I. Valkengoed, W.K. Redekop & K. Stronks (2013). A cross-national comparative study of metabolic syndrome among non-diabetic Dutch and English ethnic groups. European Journal of Public Health, 23 (3), 447-452. doi: 10.1093/eurpub/cks041
    • S.S. Tan, L. Hakkaart-van Roijen, B.M. van Ineveld & W.K. Redekop (2013). Explaining length of stay variation of episodes of care in the Netherlands. European Journal of Health Economics (HEPAC), 14, 919-927. doi: 10.1007/s10198-012-0436-1
    • C.W.M. van Gils, M. Koopman, L. Mol, W.K. Redekop, C.A. de Uyl-de Groot & C.J.A. Punt (2012). Adjuvant chemotherapy in stage III colon cancer: Guideline implementation, patterns of use and outcomes in daily practice in The Netherlands. Acta Oncologica, 51, 57-64. doi: 10.3109/0284186X.2011.633930
    • A.A. Chote, C.J.M. de Groot, W.K. Redekop, R.J. Hoefman, G.T. Koopmans, V.W.V.K. Jaddoe, A. Hofman, E.A.P. Steegers, M.J. Trappenburg, J.P. Mackenbach & M.M.E. Foets (2012). Differences in Quality of Antenatal Care Provided by Midwives to Low-Risk Pregnant Dutch Women in Different Ethnic Groups. Journal of Midwifery & Womens Health, 57 (5), 461-468. doi: 10.1111/j.1542-2011.2012.00169.x
    • T.I. Verhoef, W.K. Redekop, R.M.F. van Schie, S. Bayat, A.K. Daly, M. Geitona, E. Haschkebecher, D.A. Hughes, F. Kamali, L.A. Levin, V.G. Manolopoulos, M. Pirmohamed, U. Siebert, J.C. Stingl, M. Wadelius, A. de Boer & A.H. Maitland-van der Zee (2012). Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. Pharmacogenomics, 13 (12), 1405-1417. doi: 10.2217/pgs.12.124
    • T.I. Verhoef, W.K. Redekop, H. Hegazy, A. de Boer & A.H. Maitland-van der Zee (2012). Long-term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users. Journal of Thrombosis and Haemostosis, 10 (12). doi: 10.1111/jth.12007
    • T.I. Verhoef, M.J.L. Zuurhout, R.M.F. van Schie, W.K. Redekop, F.J.M. van der Meer, S. le Cessie, T. Schalekamp, A. de Boer & A.H. Maitland-van der Zee (2012). The effect of omeprazole and esomeprazole on the maintenance dose of phenprocoumon. British Journal of Clinical Pharmacology, 74 (6), 1068-1069. doi: 10.1111/j.1365-2125.2012.04295.x
    • J.G. Gaultney, W.K. Redekop, P. Sonneveld & C.A. de Uyl-de Groot (2012). Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value. Expert Review of Anticancer Therapy, 12 (6), 839-854. doi: 10.1586/era.12.42 [go to publisher's site]
    • J.G. Gaultney, M.G. Franken, S.S. Tan, W.K. Redekop, P.C. Huijgens, P. Sonneveld & C.A. de Uyl-de Groot (2012). Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents. Journal of Clinical Pharmacy and Therapeutics. doi: 10.1111/jcpt.12020
    • T.I. Verhoef, W.K. Redekop, M.M. Buikema, T. Schalekamp, F.J.M. van der Meer, S. le Cessie, J.A.M. Wessels, R.M.F. van Schie, A. den Boer, M. Teichert, L.E. Visser & A.H. Zee (2012). Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users. Journal of Thrombosis and Haemostasis, 10 (4), 606-614. doi: 10.1111/j.1538-7836.2012.04633.x
    • A.M. Mendez Romero, J. Verheij, R.S. Dwarkasing, Y. Seppenwoolde, W.K. Redekop, P.E. Zondervan, P.J.C.M. Nowak, J.N.M. Ijzermans, P.C. Levendag, B.J.M. Heijmen & C. Verhoef (2012). COMPARISON OF MACROSCOPIC PATHOLOGY MEASUREMENTS WITH MAGNETIC RESONANCE IMAGING AND ASSESSMENT OF MICROSCOPIC PATHOLOGY EXTENSION FOR COLORECTAL LIVER METASTASES. International Journal of Radiation Oncology Biology Physics, 82 (1), 159-166. doi: 10.1016/j.ijrobp.2010.10.032
    • C.O. Agyemang, A.E. Kunst, R. Bhopal, K. Anujuo, P. Zaninotto, J. Nazroo, M. Nicolaou, I. Valkengoed, W.K. Redekop & K. Stronks (2011). Diabetes Prevalence in Populations of South Asian Indian and African Origins. Epidemiology, 22 (4), 563-567. doi: 10.1097/EDE.0b013e31821d1096
    • C.O. Agyemang, A.E. Kunst, R. Bhopal, P. Zaninotto, J. Nazroo, M. Nicolaou, N. Unwin, I. Valkengoed, W.K. Redekop & K. Stronks (2011). Dutch versus English advantage in the epidemic of central and generalised obesity is not shared by ethnic minority groups: comparative secondary analysis of cross-sectional data. International Journal of Obesity, 35, 1334-1346. doi: 10.1038/ijo.2010.281
    • J.G. Gaultney, W.K. Redekop, P. Sonneveld & C.A. de Uyl-de Groot (2011). Critical review of economic evaluations in multiple myeloma: An overview of the economic evidence and quality of the methodology. European Journal of Cancer, 47 (10), 1458-1467. doi: 10.1016/j.ejca.2011.04.005
    • M. Hendriks, L. Brewster, F. de Wit, O.A. Bolarinwa, A.O. Odusola, W.K. Redekop, N. Bindraban, B.A. Vollaard, S. Alli, P. Adenusi, K. Agbede, T. Akande, J. Lange & C. Schultsz (2011). Cardiovascular disease prevention in rural Nigeria in the context of a community based health insurance scheme: QUality Improvement Cardiovascular care Kwara-I (QUICK-I). Bmc Public Health, 11 (186), 1-9. doi: 10.1186/1471-2458-11-186
    • R.J. Hoefman, N.J.A. van Exel, S. Looren-de Jong, W.K. Redekop & W.B.F. Brouwer (2011). A new test of the construct validity of the CarerQol instrument: measuring the impact of informal care giving. Quality of Life Research, 20, 875-887. doi: 10.1007/s11136-010-9829-8
    • J.G. Gaultney, E. Sanhueza, J.J. Janssen, W.K. Redekop & C.A. de Uyl-de Groot (2011). Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia. Pharmacogenomics, 12 (3), 411-421. doi: 10.2217/pgs.10.187
    • A.A. Chote, C.J.M. de Groot, M.A. Bruijnzeels, W.K. Redekop, V.W.V.K. Jaddoe, A. Hofman, E.A.P. Steegers, J.P. Mackenbach & M.M.E. Foets (2011). Ethnic differences in antenatal care use in a large multi-ethnic urban population in the Netherlands. Midwifery, 27 (1), 36-41. doi: 10.1016/j.midw.2009.07.008
    • A.A. Chote, G.T. Koopmans, W.K. Redekop, C.J.M. de Groot, R.J. Hoefman, V.W.V.K. Jaddoe, A. Hofman, E.A.P. Steegers, J.P. Mackenbach, M.J. Trappenburg & M.M.E. Foets (2011). Explaining Ethnic Differences in Late Antenatal Care Entry by Predisposing, Enabling and Need Factors in the Netherlands. The Generation R Study. Maternal and Child Health Journal, 15 (6), 689-699. doi: 10.1007/s10995-010-0619-2
    • D.S. Cobden, L.W. Niessen, C.E. Barr, F.F.H. Rutten & W.K. Redekop (2010). Relationships among Self-Management, Patient Perceptions of Care, and Health Economic Outcomes for Decision-Making and Clinical Practice in Type 2 Diabetes. Value in Health, 13 (1), 138-147. doi: 10.1111/j.1524-4733.2009.00587.x
    • T.I. Verhoef, W.K. Redekop, J. Darba, M. Geitona, D.A. Hughes, U. Siebert, A. de Boer & A.H. Maitland-van der Zee (2010). A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivates. Pharmacogenomics, 11 (7), 989-1002. doi: 10.2217/pgs.10.74
    • F.G.W. Cleveringa, P.M.J. Welsing, M. van den Donk, K.J. Gorter, L.W. Niessen, G.E.H.M. Rutten & W.K. Redekop (2010). Cost-Effectiveness of the Diabetes Care Protocol; a Multifaceted Computerized Decision Support Diabetes Management Intervention That Reduces Cardiovascular Risk. Diabetes Care, 33 (2), 258-263. doi: 10.2337/dc09-1232
    • T. McLaughlin, M. Buxton, T. Mittendorf, W.K. Redekop, L. Mucha, J. Darba, L. Jonsson, L. Lacey & C. Leibman (2010). Assessment op potential measures in models of progression in Alzheimer disease. Neurology, 75, 1256-1262. doi: 10.1212/WNL.0b013e3181f6133d
    • T.I. Verhoef, T. Schalekamp, W.K. Redekop, A. de Boer & A.H. Maitland-van der Zee (2010). Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin. Expert review of pharmacoeconomics & outcomes research, 10 (4), 375-378. doi: 10.1586/erp.10.42
    • D.S. Cobden, L.W. Niessen, F.F.H. Rutten & W.K. Redekop (2010). Modeling the economic impact of medication adherence in type 2 diabetes: a theoretical approach. Patient Preference and Adherence, 4, 283-290.
    • S.S. Tan, B.M. van Ineveld, W.K. Redekop & L. Hakkaart-van Roijen (2009). Comparing Methodologies for the Allocation of Overhead and Capital Costs to Hospital Services. Value in Health, 12 (4), 530-535. doi: 10.1111/j.1524-4733.2008.00475.x
    • S.S. Tan, F.F.H. Rutten, B.M. van Ineveld, W.K. Redekop & L. Hakkaart-van Roijen (2009). Comparing methodologies for the cost estimation of hospital services. European Journal of Health Economics (HEPAC), 10, 39-45. doi: 10.1007/s10198-008-0101-x
    • Z. Niazkhani, H. van der Sijs, H. Pirnejad, W.K. Redekop & J.E.C.M. Aarts (2009). Same system, different outcomes: Comparing the transitions from two paper-based systems to the same computerized physician order entry system. International Journal of Medical Informatics, 78, 170-181. doi: 10.1016/j.ijmedinf.2008.06.012
    • R.M.F. van Schie, M. Wadelius, F. Kamali, A.K. Daly, V.G. Manolopoulos, A. de Boer, R. Barallon, T.I. Verhoef, J. Kirchheiner, M. Haschke-Becher, M. Briz, F.R. Rosendaal, W.K. Redekop, M. Pirmohamed & A.H. Maitland - van der Zee (2009). Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacoeconomics (Print), 10 (10), 1287-1295. doi: 10.2217/pgs.09.125
    • S.S. Tan, W.K. Redekop & F.F.H. Rutten (2008). Costs and prices of single dental fillings in Europe: a micro-costing study. Health Economics, 83-93. doi: 10.1002/hec.1326
    • E.M. Delhaas, N. Beersen, W.K. Redekop & N.S. Klazinga (2008). Long-term outcomes of continuous intrathecal baclofen infusion for treatment of spasticity: a prospective multicenter follow-up study. Neuromodulation, 227-236. doi: 10.1111/j.1525-1403.2008.00170.x
    • W.K. Redekop, E. Orlewska, P. Maciejewski, F.F.H. Rutten & L.W. Niessen (2008). Costs and Effects of Secondary Prevention with Perindopril in Stable Coronary Heart Disease in Poland. Pharmacoeconomics (Print), 26, 861-877.
    • H.E. Hart, W.K. Redekop, H.J.G. Bilo, B. Meyboom- de Jong & M. Berg (2007). Health related quality of life in patients with type I diabetes mellitus: generic & disease-specific measurement. Indian Journal of Medical Research, 125, 203-216.
    • C.O. Agyemang, R. Bhopal & W.K. Redekop (2007). Does the pulse pressure in people of European, African and South Asian descent differ? A systematic review and meta-analysis of UK data. Journal of Human Hypertension, 21, 598-609. doi: 10.1038/sj.jhh.1002191
    • J.J. Visser, M.R.H.M. Sambeek, M.G.M. Hunink, W.K. Redekop, L.C. van Dijk, J.M. Hendriks & J.L. Bosch (2006). Acute abdominal aortic aneurysms: cost analysis of endovascular repair and open surgery in hemodynamically stable patients with 1-year follow-up. Radiology, 240 (3), 681-689. doi: 10.1148/radiol.2403051005
    • W.B.F. Brouwer, N.J.A. van Exel, B. van Gorp & W.K. Redekop (2006). The CarerQol instrument: A new instrument to measure care-related quality of life of informal caregivers for use in economic evaluations. Quality of Life Research, 15, 1005-1021. doi: 10.1007/s11136-005-5994-6
    • J.J. Visser, M.R.H.M. van Sambeek, M.G.M. Hunink, W.K. Redekop, L.C. van Dijk, J.M. Hendriks & J.L. Bosch (2006). Cost analysis of endovascular repari and open surgery in patients with acute abdominal aortic aneurysms with one-year-follow-up. Radiology, 240, 681-689.
    • W.K. Redekop (2006). Cost-effectiveness analyses of diagnostic strategies: a literature survey using the NHS Economic Evaluation Database. Future Drugs, 6 (1), 41-48. doi: 10.1586/14737167.6.1.41
    • H.E. Hart, W.K. Redekop, M. Berg, H.J.G. Bilo & B. Meyboom- de Jong (2005). Factors that predicted change in health-related quality of life were identified in a cohort of diabetes mellitus type 1 patients. Journal of Clinical Epidemiology, 58, 1158-1164. doi: 10.1016/j.jclinepi.2005.02.021
    • C.O. Agyemang, W.K. Redekop, E. Owusu-Dabo & M.A. Bruijnzeels (2005). Blood pressure patterns in rural, semi-urban and urban children in the Ashanti region of Ghana, West Africa. BMC Public Health, 5. doi: 10.1186/1471-2458-5-114
    • C.O. Agyemang, R. Bhopal, M.A. Bruijnzeels & W.K. Redekop (2005). Does the white-coat effect in people of African and South Asian descent differ from that in White people of European origin? A systematic review and meta-analysis. Blood Pressure Monitoring, 10 (5), 243-248. doi: 10.1097/01.mbp.0000172712.89910.e4
    • H.E. Hart, W.K. Redekop, H.J.G. Bilo, M. Berg & B. Jong (2005). Change in perceived health and functioning over time in patients with type I diabetes mellitus. Quality of Life Research, 14, 1-10. doi: 10.1007/s11136-004-0782-2
    • N. Beersen, W.K. Redekop, J.H.B. de Bruijn, P.J. Theuvenet, M. Berg & N.S. Klazinga (2005). Quality based social insurance coverage and payment of the application of a high cost medical therapy: the case of spinal cord stimulation for chronic non-oncologic pain in The Netherlands. Health Policy, 71 (1), 107-115. doi: 10.1016/j.healthpol.2004.08.002
    • J. de Raad & W.K. Redekop (2005). Analysis of health factors as predictors for the funcitoning of military personnel: study of the factors that predict fitness for duty and medical costs of soldiers of the Royal Netherlands Army. Military Medicine, 170, 14-20.
    • C.O. Agyemang, R. Bhopal, M.A. Bruijnzeels & W.K. Redekop (2005). Does nocturnal blood pressure fall in people of African and South Asian descent differ from that in European white populations? A systematic review and meta-analysis. Journal of Hypertension, 23 (5), 913-920.
    • M.J.M.H. Lombarts, N.S. Klazinga & W.K. Redekop (2005). Measuring the perceived impact of facilitation on implementing recommendations from external assessment: lessons from the Dutch visitatie programme for medical specialists. Journal of Evaluation in Clinical Practice, 11 (6), 587-597. doi: 10.1111/j.1365-2753.2005.00595.x
    • N. Beersen, J.H.B. de Bruijn, M.A. Dekkers, P. ten Have, G. Hekster, W.K. Redekop, G.H.J.J. Spincemaille, P.J. Theuvenet, M. Berg & N.S. Klazinga (2004). Developing a national continuous quality improvement system for neuromodulation treatment in the Netherlands. Journal of Quality and Safety. Joint Commission Journal on Quality Improvement, 30, 310-321.
    • W.K. Redekop, E.A. Stolk, E. Kok, K. Lovas, Z. Kalo & J.J. van Busschbach (2004). Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments. Diabetes & Metabolism, 30, 549-556.
    • M.M. Ortegon, W.K. Redekop & L.W. Niessen (2004). Cost-effectiveness of prevention and treatment of the diabetic foot. Diabetes Care, 27, 901-907. doi: 10.2337/diacare.27.4.901
    • W.K. Redekop (2004). Does improved glycaemic control lead to a better short-term quality of life in diabetes mellitus type 2? Postgraduate Medical Journal, 50, 194-194.
    • H.E. Hart, H.J.G. Bilo, W.K. Redekop & R.P. Stolk (2003). Quality of life of patients with type I diabetes mellitus. Quality of Life Research, 12, 1089-1097.
    • W.K. Redekop, J. Mcdonnell, P. Verboom, K. Lovas & Z. Kalo (2003). The cost effecitveness of Apligraf treatment of diabetic foot ulcers. Pharmacoeconomics (Print), 21 (16), 1171-1183. doi: 10.2165/00019053-200321160-00003
    • W.K. Redekop, M.A. Koopmanschap, E.A. Stolk, F.F.H. Rutten, B.H.R. Wolffenbuttel & L.W. Niessen (2002). Health related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care, 25 (3), 458-463. doi: 10.2337/diacare.25.3.458
    • R. Oostenbrink, J.B. Oostenbrink, K.G.M. Moons, G. Derksen-Lubsen, M.L. Bot, D.E. Grobbee, W.K. Redekop & H.A. Moll (2002). Cost-utility analysis of patient care in children with meningeal signs. International Journal of Technology Assessment in Health Care, 18 (3), 485-496.
    • W.K. Redekop, M.A. Koopmanschap, F.F.H. Rutten, B.H.R. Wolffenbuttel, E.A. Stolk & L.W. Niessen (2002). Resource consumption and costs in Dutch patients with Type II diabetes mellitus. Results from 29 general practices. Diabetic Medicine, 19, 246-253. doi: 10.1046/j.1464-5491.2002.00654.x
    • H.E. Hart, W.K. Redekop, H.J.G. Bilo, J.H. Assink & A.F. Casparie (2001). Quality of life in patients with type I diabetes mellitus. Netherlands Journal of Medicine, 58, 2-2.
    • E.M. Koomen, B.A. Hutten, J.C. Kelder, W.K. Redekop, J.G.P. Tijssen & J.H. Kingma (2001). Morbidity and mortality in patients waiting for coronary artery bypass surgery. European Journal of Cardio-Thoracic Surgery, 19 (3), 260-265.
    • R. Jansen, W.K. Redekop & F.F.H. Rutten (2001). Cost effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis: an analysis of based on results from the L.I.O.N. study, Lamisil versus Itraconazole in Onychomycosis. Pharmacoeconomics (Print), 19 (4), 401-410.
    • J. Mcdonnell, W.K. Redekop, N. van der Roer, E.S. Goes, A. Ruitenberg, J.J. van Busschbach, M.M.B. Breteler & F.F.H. Rutten (2001). The costs of treatment of Alzheiemers's disease in The Netherlands. A regression-based simulation model. Pharmacoeconomics (Print), 19 (4), 379-390.
    • A. Ruitenberg, S. Kalmijn, M.A.J. de Ridder, W.K. Redekop, F. van Harskamp & A. Hof (2001). Prognosis of Alzheimer's Disease: The Rotterdam Study. Neuroepidemiology, 20 (3), 188-195. doi: 10.1159/000054786
    • L. Hakkaart-van Roijen, P. Verboom, W.K. Redekop, C.R. Touw & F.F.H. Rutten (2001). The cost effectiveness of tapered versus abrupt discontinuation of oral cyclosporin microemulsion for the treatment of psoriasis. Pharmacoeconomics (Print), 19, 599-608.

  • Professional Publication (5)

    • M. Westwood, H. Raatz, K. Misso, L.T. Burgers, W.K. Redekop, S.K. Lhachimi, N. Armstrong & J. Kleijnen (2013). Systematic review of the accuracy of dual-source cardiac CT for detection of arterial stenosis in difficult to image patient groups. Radiology, 267 (2), 387-395. doi: 10.1148/radiol.13121136/-/DC1
    • C.O. Agyemang, A.E. Kunst, R. Bhopal, P. Zaninotto, N. Unwin, J. Nazroo, M. Nicolaou, W.K. Redekop & K. Stronks (2011). Hypertensie in Nederlandse en Engelse etnische minderheidsgroepen. Nederlands Tijdschrift voor Geneeskunde, A3318 (155), 1-9.
    • B.M. van Ineveld, P.J.G. Dohmen & W.K. Redekop (2006). De startende marktwerking in de gezondheidszorg. Economisch-Statistische Berichten, 91 (4494), 470-473.
    • J. de Raad & W.K. Redekop (2004). A comparison between two systems for pre-employment medical assessment in the Royal Netherlands Army by a randomized, controlled study. Military Medicine, 169, 437-443.
    • W.K. Redekop & M.A. Koopmanschap (2004). Economische aspecten van polyfarmacie bij diabetes. CBO, 8-22.

• Part of book - Chapter (5)

  • Scholarly Publication (4)

    • K. Phillips, K. Payne & W.K. Redekop (2016). Personalized Medicine: Economic Evaluation and Evidence. In R.M. Scheffler (Ed.), World Scientific Handbook of Global Health Economics and Public Policy: Volume 2: Health Determinants and Outcomes (pp. 123-150). World Scientific
    • R.M.F. van Schie, T.I. Verhoef, A.H. Maitland-van der Zee, A. de Boer, F.J.M. van der Meer, W.K. Redekop & R. Thariani (2012). Future of Pharmacogenetics in Cardiovascular Diseases. In L. Gallelli (Ed.), Pharmacology (pp. 207-222). Rijeka: InTech
    • S.S. Tan, L. Serden, A. Geissler, B.M. van Ineveld, W.K. Redekop, M. Heurgren & L. Hakkaart-van Roijen (2011). DRGs and cost accounting: Which is driving which? In R. Busse, A. Geissler, W. Quentin & M. Wiley (Eds.), Diagnosis - Related Groups in Europe (pp. 61/5-74/5). Berkshire, England: Open University Press
    • S.S. Tan, B.M. van Ineveld, W.K. Redekop & L. Hakkaart-van Roijen (2011). The Netherlands: The Diagnose Behandeling Combinaties. In R. Busse, A. Geissler, W. Quentin & M. Wiley (Eds.), Diagnosis - Related Groups in Europe (pp. 425/23-446/23). Berkshire, England: Open University Press

  • Professional Publication (1)

    • W.K. Redekop (2017). Personalised medicine to improve cardiovascular health. In W. French, M. Hulse & D.J. Singer (Eds.), The Hippocrates Book of the Heart (pp. 159-161). London, UK: The Hippocrates Press

• Report (4)

  • Professional Publication (3)

    • M. Westwood, M.J. Al, L.T. Burgers, W.K. Redekop, S.K. Lhachimi, N. Armstrong, H. Raatz, K. Misso, J.L. Severens & J. Kleijnen (2013). A systematic review and economic evaluation of new-generation computed tomography scanners for imaging in coronary artery disease and congenital heart disease: Somatom Definition Flash, Aquilion ONE, Brilliance iCT and Discovery CT750 HD. (Extern rapport, 17, no 9). United Kingdon: Health Technology Assessment
    • I.N. Fabbricotti, M. Oud, W.K. Redekop & R. Huijsman (2011). De meerwaarde van HKZ-certificering voor GGZ-instelling. (Extern rapport). Rotterdam: Erasmus Universiteit Rotterdam
    • N. van der Roer, J.J. van Busschbach, E.S. Goes, L. Hakkaart-van Roijen & W.K. Redekop (2001). Kosten van de ziekte van Alzheimer; een studie naar de belangrijkste kostenposten voor patiënten met de ziekte van Alzheimer in Nederland en in Frankrijk. (Intern rapport, no 01.56). :

  • Other Publication (1)

    • M.G. Franken, J.G. Gaultney, H.M. Blommestein, S.S. Tan, C.W.M. van Gils, P.C. Huijgens, P. Sonneveld, W.K. Redekop & C.A. de Uyl-de Groot (2012). Pilot outcomes research: effects and costs of bortezomib in relapsed or refractory multiple myeloma. (Extern rapport). Rotterdam: Erasmus Universiteit Rotterdam - GE-iMTA [go to publisher's site]

• Other output (1)

  • H.E. Hart, W.K. Redekop, H.J.G. Bilo, J.J. van Busschbach & A.F. Casparie (2001). Quality of life over time in a cohort of patients with type 1 diabetes mellitus measured with the Euroqol and the SF-36. 17 th. Plenary meeting of the Euroqol group: Pamplona, Spain (2001, september 28).

• Award (1)

  • A. Ansaripour, K. Zendehdel, N. Tadayon, F. Sadeghi, C.A. de Uyl-de Groot & W.K. Redekop (2016). Use of data-mining to perform a real world cost analysis of HER2-positive breast cancer in Iran. 19th Annual European Congress: Vienna - Austeria (2016, oktober 29 - 2016, november 2). Overig.

• Supervised Theses (9)

  • E.J. Lenk (2019, december 19). Diseases of the Poor: the Socioeconomic Impact of Neglected Tropical Diseases. EUR Prom./coprom.: prof.dr. J.L. Severens, Prof. Dr. S.J. de Vlas & dr. W.K. Redekop.
  • A. Ansaripour (2018, juli 6). Improving decision-making for drug reimbursement in Iran. EUR Prom./coprom.: prof.dr. C.A. de Uyl-de Groot & dr. W.K. Redekop.
  • L.R. Buisman (2016, juni 30). Early cost-effectiveness of medical tests in rheumatoid arthritis and ischemic stroke. EUR Prom./coprom.: prof.dr. M.P.M.H. Rutten - van Molken & dr. W.K. Redekop.
  • H.J. Fugel (2016, juni 17). Economics of Stratified Medicine. Rijksuniversiteit Groningen Prom./coprom.: M. Postma, dr. M.J. Nuijten & dr. W.K. Redekop.
  • S. de Groot. Evidence from clinical practice to support healthcare decision making, evaluation of clinical and economic outcomes of new therapies for metastatic renal cell carcinoma. EUR Prom./coprom.: prof.dr. C.A. de Uyl-de Groot, L.A.L.M. Kiemeney & dr. W.K. Redekop.
  • A. Leunis. The cost-effectiveness of personalized medicine strategies in acute myeloid leukemia. EUR Prom./coprom.: prof.dr. C.A. de Uyl-de Groot, Prof. Dr. B. Lowenberg & dr. W.K. Redekop.
  • L.T. Burgers. Challenges in Assessing the Cost-Effectiveness of cardiovascular disease technologies. EUR (217 pag.) (Enschede: Ipskamp drukkers) Prom./coprom.: prof.dr. J.L. Severens & dr. W.K. Redekop.
  • C.W.M. van Gils (2013, december 19). Real-world cost-effectiveness. EUR (214 pag.) (Rotterdam) Prom./coprom.: prof.dr. C.A. de Uyl-de Groot, C.J.A. Punt & dr. W.K. Redekop.
  • L.M.A. Goossens (2013, januari 18). Underestimated uncertainties: hospital-at-home for COPD exacerbations and methodological issues in the economic evaluation of healthcare. EUR (215 pag.) (Rotterdam) Prom./coprom.: prof.dr. M.P.M.H. Rutten - van Molken, C.P. van Schayck & dr. W.K. Redekop.

Teaching (10)

Present position